Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27768646 | 0.82 | ALDH1A1 (0.74) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL287420 | 0.82 | ALDH1A1 (0.74) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL6706804 | 0.79 | ALDH1A1 (0.70) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL2866244 | 0.79 | HDAC1 (0.71) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL893099 | 0.79 | ALDH1A1 (1.00) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL167905 | 0.79 | HDAC1 (0.74) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL1683862 | 0.78 | ALDH1A1 (0.68) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL19382473 | 0.75 | HDAC1 (0.74) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL2554554 | 0.75 | HDAC1 (0.74) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL6386434 | 0.75 | HDAC1 (0.65) | ALDH1A1HDAC1HDAC8HDAC6PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE, | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | ALDH1A1 1721/4885HDAC1 2333/4885HDAC8 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.